

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION

^{Pr} **APO-PREDNISONONE**

Prednisone Tablets

Tablets, 1 mg, 5 mg and 50 mg, Oral

USP

Glucocorticoid

APOTEX INC.
150 Signet Drive
Toronto, Ontario
M9L 1T9

Date of Initial Authorization:
MAR 30, 2015

Date of Revision:
OCT 02, 2025

Submission Control Number: 298353

RECENT MAJOR LABEL CHANGES

2 CONTRAINDICATIONS	10/2025
3 SERIOUS WARNINGS AND PRECAUTIONS BOX	10/2025
4 DOSAGE AND ADMINISTRATION, 4.1 Dosing Considerations	10/2025
7 WARNINGS AND PRECAUTIONS, General	10/2025
7 WARNINGS AND PRECAUTIONS, Cardiovascular	10/2025
7 WARNINGS AND PRECAUTIONS, Endocrine and Metabolism	10/2025
7 WARNINGS AND PRECAUTIONS, Hepatic/Biliary/Pancreatic	10/2025
7 WARNINGS AND PRECAUTIONS, Immune	10/2025
7 WARNINGS AND PRECAUTIONS, Monitoring and Laboratory Tests	10/2025
7 WARNINGS AND PRECAUTIONS, Musculoskeletal	10/2025
7 WARNINGS AND PRECAUTIONS, Ophthalmologic	10/2025
7 WARNINGS AND PRECAUTIONS, Psychiatric	10/2025
7 WARNINGS AND PRECAUTIONS, Renal	10/2025
7 WARNINGS AND PRECAUTIONS, 7.1.1 Pregnant Women	10/2025
7 WARNINGS AND PRECAUTIONS, 7.1.3 Pediatrics	10/2025

TABLE OF CONTENTS

Certain sections or subsections that are not applicable at the time of the preparation of the most recent authorized product monograph are not listed.

RECENT MAJOR LABEL CHANGES	2
TABLE OF CONTENTS	2
PART I: HEALTH PROFESSIONAL INFORMATION	5
1 INDICATIONS	5
1.1 Pediatrics	6
1.2 Geriatrics	6
2 CONTRAINDICATIONS	6
3 SERIOUS WARNINGS AND PRECAUTIONS BOX	7
4 DOSAGE AND ADMINISTRATION	7
4.1 Dosing Considerations	7

4.2	Recommended Dose and Dosage Adjustment	8
4.4	Administration.....	10
4.5	Missed Dose	10
5	OVERDOSAGE.....	10
6	DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING	11
7	WARNINGS AND PRECAUTIONS	11
7.1	Special Populations.....	19
7.1.1	Pregnant Women	19
7.1.2	Breast-feeding	19
7.1.3	Pediatrics.....	20
7.1.4	Geriatrics	20
8	ADVERSE REACTIONS	20
8.1	Adverse Reaction Overview.....	20
8.5	Post-Market Adverse Reactions	26
9	DRUG INTERACTIONS	27
9.2	Drug Interactions Overview	27
9.3	Drug-Behavioural Interactions.....	27
9.4	Drug-Drug Interactions	27
9.5	Drug-Food Interactions.....	35
9.6	Drug-Herb Interactions.....	36
9.7	Drug-Laboratory Test Interactions.....	36
10	CLINICAL PHARMACOLOGY	36
10.1	Mechanism of Action.....	36
10.2	Pharmacodynamics	37
10.3	Pharmacokinetics	38
11	STORAGE, STABILITY AND DISPOSAL	40
12	SPECIAL HANDLING INSTRUCTIONS.....	40
PART II: SCIENTIFIC INFORMATION		41
13	PHARMACEUTICAL INFORMATION	41
14	CLINICAL TRIALS	41
15	MICROBIOLOGY	41

16 NON-CLINICAL TOXICOLOGY 41
PATIENT MEDICATION INFORMATION..... 43

PART I: HEALTH PROFESSIONAL INFORMATION

1 INDICATIONS

APO-PREDNISONE (prednisone) is indicated for:

- **Adrenocortical function abnormalities:** Chronic primary adrenocortical insufficiency (Addison's disease) together with mineralocorticoid or sodium supplementation; secondary adrenocortical insufficiency; adrenogenital syndrome (congenital adrenal hyperplasia).
- **Allergic Disorders:** Drug-induced allergic reactions; adjunct treatment in anaphylactic or anaphylactoid reactions; adjunct treatment in angioedema; severe allergic, perennial or seasonal rhinitis; serum sickness.
- **Collagen Disorders:** Maintenance therapy in selected cases of acute rheumatic carditis; systemic dermatomyositis in children; systemic lupus erythematosus.
- **Dermatologic Disorders:** Atopic dermatitis; contact dermatitis; exfoliative dermatitis; bullous herpetiformis dermatitis; severe multiforme erythema (Stevens-Johnson syndrome); mycosis fungoides; pemphigus; severe psoriasis.
- **Gastrointestinal disorders:** Inflammatory bowel disease; regional enteritis (Crohn's disease).
- **Hematologic disorders:** Autoimmune hemolytic anemia; congenital hypoplastic anemia; erythroblastopenia; adult secondary thrombocytopenia; idiopathic thrombocytopenic purpura in adults.
- **Nonrheumatic Inflammation:** Acute or subacute bursitis; nonspecific acute tendosynovitis.
- **Neoplastic Diseases (adjunct treatment):** Indicated in conjunction with appropriate specific antineoplastic disease therapy for the palliative treatment of the following neoplastic diseases and related problems acute or chronic lymphocytic leukemia; Hodgkin's or non-Hodgkin's lymphoma.
- **Nephrotic syndrome:** Indicated to induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome (without uremia), and to improve renal function in patients with lupus erythematosus. In idiopathic nephrotic syndrome, long-term therapy may be required to prevent frequent relapses.
- **Neurologic disease:** Adjunct treatment in tuberculous meningitis in patients with concurrent or impending subarachnoid block.
- **Ophthalmic disorders:** Chorioretinitis; diffuse posterior choroiditis; allergic, not topically controlled, conjunctivitis; herpes zoster; iridocyclitis; keratitis not associated with herpes simplex or fungal infection; optic neuritis; sympathetic ophthalmia; diffuse posterior uveitis.
- **Respiratory disorders:** Bronchial asthma; berylliosis; Loeffler syndrome (eosinophilic

pneumonitis or hypereosinophilic syndrome); aspiration pneumonitis; symptomatic sarcoidosis; adjunct treatment in disseminated or fulminating pulmonary tuberculosis.

- **Rheumatic disorders:** Adjunctive therapy in ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis (including juvenile arthritis); acute gouty arthritis.
- **Thyroiditis:** Nonsuppurative thyroiditis.

1.1 Pediatrics

Pediatrics (< 6 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of APO-PREDNISONE in pediatric patients has not been established; therefore, Health Canada has not authorized an indication for pediatric use. See [4.2 Recommended Dose and Dosage Adjustment, Pediatric dose](#).

Pediatrics (6 to 18 years of age): See [4.2 Recommended Dose and Dosage Adjustment, Pediatric dose](#) and [7.1.3 Pediatrics](#).

1.2 Geriatrics

Geriatrics (> 65 years of age): Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness. See [4.2 Recommended Dose and Dosage Adjustment, Geriatric dose](#) and [7.1.4. Geriatrics](#).

2 CONTRAINDICATIONS

APO-PREDNISONE (prednisone) is contraindicated in:

- Patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. For a complete listing, see [6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING](#).
- Systemic fungal infections.
- Patients administered with live or live, attenuated vaccines while receiving immunosuppressive doses of glucocorticoids.
- Herpes simplex of the eye, except when used for short-term or emergency therapy as in acute sensitivity reactions.
- Patients with measles and chickenpox, except when used for short-term or emergency therapy as in acute sensitivity reactions.
- Patients with peptic ulcers and nonspecific ulcerative colitis.
- Patients with diverticulitis.
- Peptic with viral or bacterial infection not controlled by anti infectives.
- Pancreatitis (except pancreatitis caused by sarcoidosis).

3 SERIOUS WARNINGS AND PRECAUTIONS BOX

Serious Warnings and Precautions

- **Pheochromocytoma crisis:** Pheochromocytoma crisis, which can be fatal, has been reported after administration of systemic glucocorticoids. See [7 WARNINGS AND PRECAUTIONS, Endocrine and Metabolism](#).
- **Viral Infections:** Children who are on immunosuppressant drugs are more susceptible to infections than healthy children. Viral infections, such as chickenpox and measles, can have a more serious or even fatal course in non-immune children or adults on glucocorticoids. See [7 WARNINGS AND PRECAUTIONS, Immune, Viral Infections](#).
- **Scleroderma renal crisis:** Caution is required in patients with systemic sclerosis because of an increased incidence of (possibly fatal) scleroderma renal crisis with hypertension and decreased urinary output observed with a daily dose of 15 mg or more prednisone tablet. See [7 WARNINGS AND PRECAUTIONS, Renal, Scleroderma renal crisis](#).
- **Strongyloides (threadworm) infestation:** Glucocorticoids should be used with great care in patients with known or suspected Strongyloides (threadworm) infestation. In such patients, glucocorticoid-induced immunosuppression may lead to Strongyloides hyperinfection and dissemination with widespread larval migration, often accompanied by severe enterocolitis and potentially fatal gram-negative septicemia. See [7 WARNINGS AND PRECAUTIONS, Immune, Special pathogens](#)

4 DOSAGE AND ADMINISTRATION

4.1 Dosing Considerations

- Dose ranges for glucocorticoids are extremely wide, and patient responses are quite variable. The amount of drug each patient receives should be individualized according to the diagnosis, severity, prognosis and probable duration of the disease, and patient response and tolerance.
- In the management of acute disorders, glucocorticoid dosage should be sufficient to ensure that symptoms are controlled quickly, and treatment should be discontinued as soon as possible. Acute disorders respond most rapidly to divided daily doses. In life-threatening situations where adrenal insufficiency may be the precipitating cause, glucocorticoids can be administered in any dosage required without serious complications, even before a definite diagnosis has been made.
- After a favorable response is noted, the proper maintenance dosage should be determined by decreasing the initial drug dosage in small decrements at appropriate time intervals until the lowest dosage which will maintain an adequate clinical response is reached.
- In situations of less severity lower doses will generally suffice while in selected patients higher initial doses may be required. The initial dosage should be maintained or adjusted until a satisfactory response is noted. If after a reasonable period of time there

is a lack of satisfactory clinical response, APO-PREDNISONONE should be discontinued and the patient transferred to other appropriate therapy.

- Long-term glucocorticoid therapy should not be initiated without due consideration of its risks. If glucocorticoids are clearly necessary, the drugs should be administered in the smallest dosage possible. Patients should be continually monitored for signs that indicate dosage adjustment is necessary, such as remission or exacerbations of the disease and stressful situations (surgery, infection, trauma) not directly related to the disease entity under treatment; in this latter situation it may be necessary to increase the dosage of APO-PREDNISONONE for a period of time consistent with the patient's condition. Periodic attempts should be made to decrease dosage or, preferably, to withdraw the drugs completely.
- Equipotent doses of glucocorticoids are: cortisone 5 mg; hydrocortisone 4 mg; prednisone 1 mg and prednisolone 1 mg.
- **Discontinuation of Therapy:** Although high-dose glucocorticoid therapy used for only brief periods in emergency situations may be reduced and discontinued quite rapidly, long-term therapy with pharmacologic doses of glucocorticoids may result in hypothalamic-pituitary adrenal (HPA) axis suppression by inhibiting the release of ACTH. Therefore, withdrawal following long-term therapy with pharmacologic dosages of glucocorticoids should be very gradual until recovery of HPA-axis function occurs. The time required for complete HPA function recovery following discontinuation of glucocorticoid therapy is variable.

Maintenance therapy can be discontinued when:

- Normal morning plasma cortisol concentrations greater than 10 ug/dL.
- Response to a ACTH test is normal.

If sudden cessation of treatment is necessary, ACTH may be administered to avoid withdrawal symptoms.

4.2 Recommended Dose and Dosage Adjustment

Adult dose

- Usual adult dose is 5 to 60 mg a day as a single dose or in divided doses.
- Adult prescribing limit is 250 mg daily.

Pediatric dose

- This dosage form is not suitable for children less than 6 years old.
- For children over 6 years old, the recommended dosage should be governed by the same considerations as that for adults.
- Prolonged therapy with glucocorticoids in children should be avoided, if possible, as glucocorticoids may suppress growth. If chronic therapy is essential, then alternative day therapy should be considered to minimize this side effect.

Geriatric dose

- In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range. See [7.1.4 Geriatrics](#).

Alternate-Day Therapy

Alternate-day therapy (ADT) is the dosage regimen of choice for long-term oral glucocorticoid treatment of most conditions. In alternate-day therapy, a single dose is administered every other morning. The drug is administered in the morning to simulate the natural circadian rhythm of glucocorticoid secretion which is high in the morning and low in the evening. This regimen provides relief of symptoms while minimizing adrenal suppression, protein catabolism, and other adverse effects including the cushingoid state, corticoid withdrawal symptoms, and growth suppression in children. To change patients from initial divided-dose oral therapy to alternate-day therapy, twice the total daily dose that has been found to be effective may be administered as a single dose every other morning; this dose may then be gradually decreased to maintenance levels.

The rationale for this treatment schedule is based on two major premises: (a) the anti-inflammatory or therapeutic effect of corticoids persists longer than their physical presence and metabolic effects and (b) administration of the corticosteroid every other morning allows for re-establishment of more nearly normal HPA activity on the off-steroid day.

Although it has been shown that there is considerably less adrenal suppression following a single morning dose of prednisolone (10 mg) as opposed to a quarter of that dose administered every 6 hours, there is evidence that some suppressive effect on adrenal activity may be carried over into the following day when pharmacologic doses are used. Further, it has been shown that a single dose of certain corticosteroids will produce adrenocortical suppression for two or more days. Other corticoids, including methylprednisolone, hydrocortisone, prednisone, and prednisolone, are considered to be short acting (producing adrenocortical suppression for 1¼ to 1½ days following a single dose) and thus are recommended for alternate day therapy.

The following should be kept in mind when considering alternate day therapy:

- 1) Basic principles and indications for corticosteroid therapy should apply. The benefits of ADT should not encourage the indiscriminate use of steroids.
- 2) ADT is a therapeutic technique primarily designed for patients in whom long-term pharmacologic corticoid therapy is anticipated.
- 3) In less severe disease processes in which corticoid therapy is indicated, it may be possible to initiate treatment with ADT. More severe disease states usually will require daily divided high dose therapy for initial control of the disease process. The initial suppressive dose level should be continued until satisfactory clinical response is obtained, usually four to ten days in the case of many allergic and collagen diseases. It is important to keep the period of initial suppressive dose as brief as possible particularly when subsequent use of alternate day therapy is intended.

Once control has been established, two courses are available: (a) change to ADT and then gradually reduce the amount of corticoid given every other day or (b) following

control of the disease process reduce the daily dose of corticoid to the lowest effective level as rapidly as possible and then change over to an alternate day schedule. Theoretically, course (a) may be preferable.

- 4) Because of the advantages of ADT, it may be desirable to try patients on this form of therapy who have been on daily corticoids for long periods of time (eg, patients with rheumatoid arthritis). Since these patients may already have a suppressed HPA axis, establishing them on ADT may be difficult and not always successful. However, it is recommended that regular attempts be made to change them over. It may be helpful to triple or even quadruple the daily maintenance dose and administer this every other day rather than just doubling the daily dose if difficulty is encountered. Once the patient is again controlled, an attempt should be made to reduce this dose to a minimum.
- 5) As indicated above, certain corticosteroids, because of their prolonged suppressive effect on adrenal activity, are not recommended for alternate day therapy (eg, dexamethasone and betamethasone).
- 6) The maximal activity of the adrenal cortex is between 2 am and 8 am, and it is minimal between 4 pm and midnight. Exogenous corticosteroids suppress adrenocortical activity the least, when given at the time of maximal activity (am).
- 7) In using ADT it is important, as in all therapeutic situations to individualize and tailor the therapy to each patient. Complete control of symptoms will not be possible in all patients. An explanation of the benefits of ADT will help the patient to understand and tolerate the possible flare-up in symptoms which may occur in the latter part of the offsteroid day. Other symptomatic therapy may be added or increased at this time if needed.
- 8) In the event of an acute flare-up of the disease process, it may be necessary to return to a full suppressive daily divided corticoid dose for control. Once control is again established alternate day therapy may be re-instituted.
- 9) Although many of the undesirable features of corticosteroid therapy can be minimized by ADT, as in any therapeutic situation, the physician must carefully weigh the benefit-risk ratio for each patient in whom corticoid therapy is being considered.

4.4 Administration

APO-PREDNISONE tables should be taken orally, with water.

4.5 Missed Dose

If a dose is missed, then it should be taken as soon as possible. However, if it is almost time for the next dose, then the missed dose should be skipped and regular dosing schedule resumed. Patients should not take a double dose to make up for a missed one.

5 OVERDOSAGE

Treatment of acute overdosage is by supportive and symptomatic therapy with the dosage being reduced or the drug withdrawn. For chronic overdosage in the face of severe disease requiring continuous steroid therapy, the dosage of glucocorticoid may be reduced only temporarily, or alternate day treatment may be introduced.

For the most recent information in the management of a suspected drug overdose, contact your regional poison control centre or Health Canada's toll-free number, 1-844 POISON-X (1-844-764-7669).

6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING

Table 1 – Dosage Forms, Strengths, Composition and Packaging

Route of Administration	Dosage Form / Strength / Composition	Non-medicinal Ingredients
Oral	Tablet 1 mg, 5 mg, and 50 mg of prednisone	Croscarmellose sodium, lactose, magnesium stearate, microcrystalline cellulose.

APO-PREDNISONE 1 mg: Round, white, flat-faced with bevelled edge tablet. Engraved APO over 1 on one side, other side plain, contains prednisone 1 mg. Available in bottles of 100.

APO-PREDNISONE 5 mg: Round, white, flat-faced with bevelled edge tablet. Scored & engraved APO over 5 on one side, other side plain, contains prednisone 5 mg. Available in bottles of 100 and 1000.

APO-PREDNISONE 50 mg: Round, white, biconvex tablet. Scored and engraved APO over 50 on one side, other side plain, contains prednisone 50 mg. Available in bottles of 100.

7 WARNINGS AND PRECAUTIONS

Please see [3 SERIOUS WARNINGS AND PRECAUTIONS BOX](#).

General

In patients on glucocorticoid therapy subjected to unusual stress, increased dosage of rapidly acting glucocorticoids before, during and after the stressful situation is indicated.

Ideally corticosteroid therapy should not be instituted until a definite diagnosis has been made since the clinical signs and symptoms of disease can be masked or inhibited.

The lowest possible dose of glucocorticoid should be used to control the condition under treatment and when reduction in dosage is possible, the reduction should be gradual. Because complications of treatment with glucocorticoids are dependent on the size of the dose and the duration of treatment, a risk/benefit decision must be made in each individual case as to dose and duration of treatment and as to whether daily or intermittent therapy should be used.

Advise patients to inform subsequent physicians of the prior use of glucocorticoids.

Withdrawal Symptoms: Symptoms of withdrawal from glucocorticoid therapy associated with adrenal insufficiency include malaise, muscle weakness, mental changes, desquamation of the skin, dyspnoea, anorexia, fever, dehydration, hypotension, hypoglycemia, headache, nausea, vomiting, restlessness, and muscle and joint pain. Muscle weakness and stiff joints may persist for three to six months after treatment has been discontinued. In some instances, withdrawal symptoms may simulate a clinical relapse of the disease for which the patient has been under treatment. Withdrawal of APO-PREDNISONONE should always be gradual, the rate depending on the individual patient's response, the dose and duration of therapy.

Carcinogenesis and Mutagenesis

Kaposi's sarcoma has been reported to occur in patients receiving glucocorticoid therapy. Discontinuation of glucocorticoids may result in clinical remission.

No adequate studies have been conducted in animals to determine whether glucocorticoids have a potential for carcinogenesis or mutagenesis.

Cardiovascular

Literature reports suggest an apparent association between the use of glucocorticoids and left ventricular free wall rupture after a recent myocardial infarction; therefore, therapy with glucocorticoids should be used with great caution in these patients.

As sodium retention with resultant oedema and potassium loss may occur in patients receiving glucocorticoids, these agents should be used with caution, and only if strictly necessary, in patients with congestive heart failure. Glucocorticoids should also be used with caution in patients with hypertension, or renal insufficiency. See [7 WARNINGS AND PRECAUTIONS, Renal](#).

Adverse effects of glucocorticoids on the cardiovascular system, such as dyslipidemia and hypertension, may predispose treated patients with existing cardiovascular risk factors to additional cardiovascular effects, if high doses and prolonged courses are used. Accordingly, glucocorticoids should be employed judiciously in such patients and attention should be paid to risk modification and additional cardiac monitoring if needed.

Use with caution in patients with diminished cardiac reserve.

Thrombosis including venous thromboembolism has been reported to occur with glucocorticoids. As a result glucocorticoids should be used with caution in patients who have or may be predisposed to thromboembolic disorders.

Driving and Operating Machinery

Likely to produce minor or moderate adverse effects on the ability to drive or use machinery.

Endocrine and Metabolism

Pheochromocytoma crisis, which can be fatal, has been reported after administration of systemic glucocorticoids. Glucocorticoids should only be administered to patients with suspected or identified pheochromocytoma after an appropriate risk/benefit evaluation.

During prolonged corticosteroid therapy, adrenal suppression and atrophy may occur and secretion of corticotrophin may be suppressed.

Patients should be monitored for hypothalamic-pituitary adrenal (HPA) axis suppression, Cushing's syndrome and hyperglycemia with chronic use.

Pharmacologic doses of glucocorticoids administered for prolonged periods may result in HPA suppression (secondary adrenocortical insufficiency). The degree and duration of adrenocortical insufficiency produced is variable among patients and depends on the dose, frequency, time of administration and duration of glucocorticoid therapy.

During long courses of treatment, laboratory and metabolic studies should be made. Sodium intake may need to be reduced to less than 1 g daily and calcium and potassium supplements may be necessary. Monitoring of fluid intake and output and daily weight records may give an early warning of fluid retention.

Symptoms of adrenal insufficiency include: malaise, muscle weakness, mental changes, muscle and joint pain, desquamation of the skin, dyspnoea, anorexia, nausea and vomiting, fever, hypoglycaemia, hypotension and dehydration.

Drug-induced secondary adrenocortical insufficiency may be minimized by gradual reduction of dosage. This type of relative insufficiency may persist for 6 to 12 months after discontinuation of therapy, therefore, in any situation of stress occurring during that period, hormone therapy should be reinstated. Since mineralocorticoid secretion may be impaired, salt and/or a mineralocorticoid should be administered concurrently. In addition, acute adrenal insufficiency leading to a fatal outcome may occur if glucocorticoids are withdrawn abruptly.

Because glucocorticoids can produce or aggravate Cushing's syndrome, glucocorticoids should be avoided in patients with Cushing's disease.

During prolonged therapy, any intercurrent illness, trauma or surgical procedure will require a temporary increase in dosage.

Average and large doses of hydrocortisone or cortisone can cause elevation of blood pressure, salt and water retention, and increased excretion of potassium. These effects are less likely to occur with the synthetic derivatives except when used in large doses.

All glucocorticoids increase calcium excretion. Glucocorticoids should be used with caution in patients with osteoporosis.

Glucocorticoids can increase blood glucose, worsen pre-existing diabetes, and predispose those on long-term glucocorticoid therapy to diabetes mellitus. Caution and frequent monitoring is necessary when oral corticosteroids are used in patients with diabetes mellitus or in those with a family history of diabetes.

There is an enhanced effect of glucocorticoids in patients with hypothyroidism. Caution and frequent monitoring is necessary when oral corticosteroids are used in patients with hypothyroidism.

Metabolic clearance of glucocorticoids is decreased in hypothyroid patients and increased in hyperthyroid patients. Changes in thyroid status of the patient may necessitate adjustment in dosage.

A steroid “withdrawal syndrome,” seemingly unrelated to adrenocortical insufficiency, may also occur following abrupt discontinuance of glucocorticoids. This syndrome includes symptoms such as: anorexia, nausea, vomiting, lethargy, headache, fever, joint pain, desquamation, myalgia, weight loss, and/or hypotension. These effects are thought to be due to the sudden change in glucocorticoid concentration rather than to low glucocorticoid levels.

Gastrointestinal

Glucocorticoids should be used with caution in fresh intestinal anastomoses when steroids are used as direct or adjunctive therapy, since they may increase the risk of a perforation. Signs of peritoneal irritation following gastrointestinal perforation in patients receiving glucocorticoids may be minimal or absent.

Hematologic

Acetylsalicylic acid (ASA) and nonsteroidal anti-inflammatory agents should be used cautiously in conjunction with glucocorticoids in patients with hypoprothrombinemia. See [9.4 Drug-Drug Interactions, NSAIDs \(nonsteroidal anti-inflammatory drugs\)](#).

Hepatic/Biliary/Pancreatic

Hydrocortisone may have an increased effect in patients with liver disease since the metabolism and elimination of hydrocortisone is significantly decreased in these patients. There is an enhanced effect of glucocorticoids in patients with cirrhosis.

Use with caution in patients with impaired hepatic function, a reduction of dosage may be necessary. In treating chronic active liver disease with the drug, major adverse reactions such as vertebral collapse, diabetes, hypertension, cataracts and cushing's syndrome occur in about 30% of patients.

High doses of glucocorticoids may produce acute pancreatitis.

Immune

Allergic reactions (eg, angioedema) may occur. Because rare instances of skin reactions and anaphylactic/anaphylactoid reactions have occurred in patients receiving glucocorticoid therapy, appropriate precautionary measures should be taken prior to administration, especially when the patient has a history of allergy to any drug.

Persons who are on glucocorticoids are more susceptible to infections than are healthy individuals. Suppression of the inflammatory response and immune function increases susceptibility to infections and their severity. Glucocorticoids may mask some signs of infection (such as fever and inflammation), and new infections may appear during their use. There may be decreased resistance and inability to localize infection when glucocorticoids are used. Susceptibility to infection is not specific for any particular bacterial or fungal pathogen.

Infections with any pathogen including viral, bacterial, fungal, protozoan or helminthic infections, in any location in the body, may be associated with the use of glucocorticoids alone or in combination with other immunosuppressive agents that affect cellular immunity, humoral immunity, or neutrophil function. These infections may be mild, but can be severe and at times fatal. With increasing doses of glucocorticoids, the rate of occurrence of infectious complications increases.

Glucocorticoids can increase the risk of reactivation or exacerbation of latent infections. Monitor for the development of infection and consider prednisone withdrawal or dosage reduction as needed.

Fungal Infections: Glucocorticoids may exacerbate systemic fungal infections and therefore should not be used in the presence of such infections. There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure. See [2 CONTRAINDICATIONS](#) and [9.4 Drug-Drug Interactions, Potassium-depleting agents](#).

Special pathogens: Latent disease may be activated or there may be an exacerbation of intercurrent infections due to pathogens, including those caused by Amoeba, Candida, Cryptococcus, Mycobacterium, Nocardia, Pneumocystis, Toxoplasma.

It is recommended that amebiasis be ruled out before initiating glucocorticoid therapy in any patient who has spent time in the tropics or in any patient with unexplained diarrhea.

Similarly, glucocorticoids should be used with great care in patients with known or suspected *Strongyloides* (threadworm) infestation. In such patients, glucocorticoid-induced immunosuppression may lead to *Strongyloides* hyperinfection and dissemination with widespread larval migration, often accompanied by severe enterocolitis and potentially fatal gram-negative septicemia.

Glucocorticoids should not be used in cerebral malaria. There is currently no evidence of benefit from steroids in this condition.

Tuberculosis: The use of hydrocortisone in active tuberculosis should be restricted to those cases of fulminating or disseminated tuberculosis in which the glucocorticoid is used for the management of the disease in conjunction with an appropriate anti-tuberculous regimen.

If glucocorticoids are indicated in patients with latent tuberculosis or tuberculin reactivity, close observation and caution is necessary as reactivation of the disease may occur. During prolonged glucocorticoid therapy, these patients should receive chemoprophylaxis.

Vaccination: Administration of live or live, attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of glucocorticoids and should be postponed until at least 3 months after stopping corticosteroid therapy. See [2 CONTRAINDICATIONS](#).

Killed or inactivated vaccines may be administered; however, the response to such vaccines may be diminished. Indicated immunization procedures may be undertaken in patients receiving non-immunosuppressive doses of glucocorticoids.

While on glucocorticoid therapy patients should not be vaccinated against smallpox. Other immunization procedures should not be undertaken in patients who are on glucocorticoids, especially in high doses, because of possible hazards of neurological complications and lack of antibody response. Immunization procedures may be undertaken in patients receiving corticosteroids as replacement therapy.

Viral Infections: Children who are on immunosuppressant drugs are more susceptible to infections than healthy children. Viral infections, such as chickenpox and measles, can have a more serious or even fatal course in non-immune children or adults on glucocorticoids. In non-immune children or adults who have not had these diseases, particular care should be taken to avoid exposure. If exposed, therapy with varicella zoster immune globulin (VZIG) or pooled intravenous immunoglobulin (IVIG), as appropriate, may be indicated. If chickenpox develops, treatment with antiviral agents may be considered. The contribution of the underlying disease and/or prior glucocorticoid treatment to the risk is also not known. See [2 CONTRAINDICATIONS](#).

Monitoring and Laboratory Tests

Glucocorticoids may suppress reactions to skin tests.

Dosage adjustments may be required based on the following conditions: during remission or exacerbation of the disease process; the patient's individual response to therapy; or upon exposure of the patient to emotional or physical stress such as serious infection, surgery or injury.

Monitoring for signs and symptoms of drug-induced secondary adrenocortical insufficiency may be necessary for up to one year following cessation of long-term or high-dose glucocorticoid therapy.

Frequent monitoring is necessary when oral corticosteroids are used in patients with the following conditions:

- Hypertension.
- Congestive Heart failure or recent myocardial infarction.
- Liver failure.
- Renal insufficiency.
- Osteoporosis.
- Epilepsy and/or seizure disorder.
- Patients with myasthenia gravis receiving anticholinesterase therapy since APO-PREDNISONONE may decrease plasma anticholinesterase activity.
- Patients with thromboembolic disorders.

Musculoskeletal

Caution and frequent monitoring is necessary when oral corticosteroids are used in patients with previous steroid myopathy.

An acute myopathy has been observed with the use of high doses of glucocorticoids, most often occurring in patients with disorders of neuromuscular transmission (e.g., myasthenia

gravis), or in patients receiving concomitant therapy with neuromuscular blocking drugs (e.g., pancuronium). This acute myopathy is generalized, may involve ocular and respiratory muscles, and may result in quadriplegia. Elevations of creatine kinase may occur. Clinical improvement or recovery after stopping glucocorticoids may require weeks to years.

Glucocorticoids should be used with caution in patients with myasthenia gravis receiving anticholinesterase therapy since APO-PREDNISONONE may decrease plasma anticholinesterase activity.

Osteoporosis is an adverse effect associated with long-term use of large doses of glucocorticoids. Glucocorticoids decrease bone formation and increase bone resorption both through their effect on calcium regulation (e.g., decreasing absorption and increasing excretion) and inhibition of osteoblast function. This, together with a decrease in protein matrix of the bone secondary to an increase in protein catabolism, and reduced sex hormone production, may lead to inhibition of bone growth in pediatric patients and the development of osteoporosis at any age. Special consideration should be given to patients at increased risk of osteoporosis (i.e., postmenopausal women) before initiating glucocorticoid therapy.

Caution and frequent monitoring is necessary when oral corticosteroids are used in patients with Duchenne's muscular dystrophy since transient rhabdomyolysis and myoglobinuria have been reported following strenuous physical activity.

Neurologic

Glucocorticoids should be used with caution in patients with seizure disorders.

Systemic glucocorticoids should not be used for the treatment of traumatic brain injury, as demonstrated by the results of a multicenter study. The study results revealed an increased mortality in 2 weeks and 6 months after injury in patients administered methylprednisolone sodium succinate compared to placebo.

There have been reports of epidural lipomatosis in patients taking glucocorticoids (including cases in children).

Ophthalmologic

Prolonged use of glucocorticoids may produce posterior subcapsular cataracts, and nuclear cataracts (particularly in children), exophthalmos, or increased intraocular pressure, which may result in glaucoma with possible damage to the optic nerves, and may enhance the establishment of secondary ocular infections due to bacteria, fungi, or viruses.

Caution and frequent monitoring is necessary when oral corticosteroids are used in patients with glaucoma.

As intraocular pressure may become elevated in some individuals, if steroid therapy is continued for more than 6 weeks, intraocular pressure should be monitored.

The use of oral glucocorticoids is not recommended in the treatment of optic neuritis and may lead to an increase in the risk of new episodes.

Glucocorticoids should be used cautiously in patients with ocular herpes simplex. Corticosteroids should only be initiated in patients with ocular herpes simplex with appropriate viral cover by ophthalmologists because of the risk of corneal scarring, loss of vision and corneal perforation. Glucocorticoids should not be used in active ocular herpes simplex. See [2 CONTRAINDICATIONS](#).

Glucocorticoid therapy has been associated with central serous chorioretinopathy, which may lead to retinal detachment.

Visual disturbance may be reported with systemic and topical corticosteroid use. If a patient presents with symptoms such as blurred vision or other visual disturbances, the patient should be considered for referral to an ophthalmologist for evaluation of possible causes which may include cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR) which have been reported after use of systemic and topical corticosteroids.

Psychiatric

Psychic derangements may appear when glucocorticoids are used, ranging from euphoria, insomnia, mood swings, personality changes and severe depression to frank psychotic manifestations. Also, existing emotional instability or psychotic tendencies may be aggravated by glucocorticoids.

Particular care and frequent monitoring is required when considering the use of APO-PREDNISONE in patients with existing or previous history of severe affective disorders.

Potentially severe psychiatric adverse reactions may occur with systemic steroids. Symptoms typically emerge within a few days or weeks of starting treatment. Most reactions recover after either dose reduction or withdrawal, although specific treatment may be necessary.

Psychological effects have been reported upon withdrawal of glucocorticoids; the frequency is unknown.

Patients/caregivers should be encouraged to seek medical attention if psychological symptoms develop in the patient, especially if depressed mood or suicidal ideation is suspected.

Patients/caregivers should be alert to possible psychiatric disturbances that may occur either during or immediately after dose tapering/withdrawal of systemic steroids.

Renal

As sodium retention with resultant oedema and potassium loss may occur in patients receiving glucocorticoids, these agents should be used with caution in patients with hypertension or renal insufficiency. Glucocorticoids should also be used with caution, and only if strictly necessary, in patients with congestive heart failure. See [7 WARNINGS AND PRECAUTIONS, Cardiovascular](#).

Use with caution in patients with uremia.

Scleroderma renal crisis: Caution is required in patients with systemic sclerosis because of an increased incidence of (possibly fatal) scleroderma renal crisis with hypertension and decreased urinary output observed with a daily dose of 15 mg or more APO-PREDNISONE. Blood pressure

and renal function (s-creatinine) should therefore be routinely checked. When renal crisis is suspected, blood pressure should be carefully controlled.

Reproductive Health: Female and Male Potential

- **Fertility**

Glucocorticoids may cause irregular menstruation in women, as well as abnormal spermatozoa motility and concentration.

Animal studies have shown glucocorticoids to reduce fertility in both males and females.

7.1 Special Populations

7.1.1 Pregnant Women

There are no adequate and well-controlled studies in pregnant women. In animal studies, glucocorticoids readily cross the placenta and have been shown to be teratogenic in many species when given in doses equivalent to human dose. Glucocorticoids given to pregnant mice, rats, and rabbits have yielded an increase incidence of cleft palate, skeletal malformations in the offspring, and abortion. Reduced placental and birth weight have been recorded in animals and humans after long term treatment.

Cataracts have been observed in infants born to mothers undergoing long-term treatment with glucocorticoids during pregnancy.

Since there is inadequate evidence of safety in human pregnancy, this drug should be used in pregnancy or by women of child bearing potential only if clearly needed and the potential benefit justifies the potential risk to the mother and embryo or fetus.

Infants born of mothers who have received substantial doses of glucocorticoids during pregnancy must be carefully observed and evaluated for signs of adrenal insufficiency.

The short term use of corticosteroids antepartum for the prevention of respiratory distress syndrome, does not seem to pose a risk to the fetus or the newborn infant. Maternal pulmonary oedema has been reported with tocolysis and fluid overload.

There are no known effects of glucocorticoids on labour and delivery.

7.1.2 Breast-feeding

Systemically administered glucocorticoids appear in human milk and could suppress growth, interfere with endogenous glucocorticoid production, or cause other untoward effects in breast-feeding infants.

Because of the potential for serious adverse reactions in breast-feeding infants from glucocorticoids, glucocorticoids should be administered to breast-feeding mothers only if the benefits of therapy to the mother are judged to outweigh the potential risks to the infant.

7.1.3 Pediatrics

Pediatrics (6 to 18 years of age): Pediatric patients may experience a decrease in their growth velocity observed at low systemic doses and in the absence of laboratory evidence of HPA axis. Growth velocity may therefore be a more sensitive indicator of systemic glucocorticoid exposure in pediatric patients than some commonly used tests of HPA axis function. In order to minimize the potential growth effects of glucocorticoids, pediatric patients should be titrated to the lowest effective dose over the shortest period of time. See [4.2 Recommended Dose and Dosage Adjustment, Pediatric dose](#).

Like adults, pediatric patients should be carefully observed with frequent measurements of blood pressure, weight, height, intraocular pressure, and clinical evaluation for the presence of infection, psychosocial disturbances, thromboembolism, peptic ulcers, cataracts and osteoporosis and adrenal suppression.

Infants and children on prolonged glucocorticoid therapy are at special risk from raised intracranial pressure.

High doses of glucocorticoids may produce pancreatitis in children.

7.1.4 Geriatrics

Geriatrics (> 65 years of age): In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

8 ADVERSE REACTIONS

8.1 Adverse Reaction Overview

The majority of adverse reactions from corticosteroids are those resulting from withdrawal or from prolonged use of high doses.

Note: The following are typical for all systemic glucocorticoids. Their inclusion in this list does not necessarily indicate that the specific event has been observed with this particular formulation.

Table 2 - Adverse Reactions

System Organ Class	Frequency Not Known (Cannot be estimated from available data)
Blood and lymphatic system disorders	Leukocytosis.
Cardiac disorders	Cardiac failure congestive (in susceptible patients); Bradycardia; Cardiac arrest;

System Organ Class	Frequency Not Known (Cannot be estimated from available data)
	<p>Arrhythmia; Cardiomegaly; Hypertrophic cardiomyopathy in premature infants; Myocardial rupture following recent myocardial infarction; Pulmonary oedema; Syncope; Tachycardia.</p>
Endocrine disorders	<p>Cushingoid; Pituitary-adrenal axis suppression particularly at times of stress as in trauma, surgery or illness; Hirsutism; Moon face; Suppression of growth in children; Manifestations of latent diabetes mellitus; Antagonism occurs between the parathyroids and hypercorticism. Latent hypoparathyroidism may be unmasked by administration of corticosteroids. The phosphate retention occurring in renal failure caused by adrenal insufficiency may also make hypoparathyroidism manifest.</p>
Eye disorders	<p>Cataract subcapsular (associated with prolonged, high dose systemic therapy); Exophthalmos; Glaucoma; Central serous chorioretinopathy; Corneal or scleral thinning; Exacerbation of ophthalmic viral or fungal disease.</p>
Gastrointestinal disorders	<p>Peptic ulcer (with possible perforation and hemorrhage); Gastric hemorrhage; Pancreatitis; Oesophagitis ulcerative;</p>

System Organ Class	Frequency Not Known (Cannot be estimated from available data)
	<p>Intestinal perforation (of the small and large intestine, particularly in patients with inflammatory bowel disease);</p> <p>Abdominal distension;</p> <p>Nausea;</p> <p>Hiccups;</p> <p>Dyspepsia;</p> <p>Abdominal pain;</p> <p>Diarrhoea;</p> <p>Oesophageal candidiasis;</p> <p>Vomiting;</p> <p>Constipation;</p> <p>Gastric irritation.</p>
General disorders and administration site conditions	<p>Impaired healing (usually at high doses);</p> <p>Malaise;</p> <p>Abscess sterile;</p> <p>Fatigue.</p>
Hepatobiliary disorders	Hepatomegaly.
Immune system disorders	<p>Allergic or hypersensitivity reactions (including anaphylaxis and anaphylactoid reactions [e.g. bronchospasm, laryngeal oedema, urticaria]);</p> <p>Angioedema.</p>
Infections and infestations	<p>Infection masked;</p> <p>Opportunistic infection (with any pathogen, in any location in the body, from mild to fatal);</p> <p>Infection (becoming active including reactivation of tuberculosis);</p> <p>Infection susceptibility increased.</p>
Injury, poisoning and procedural complications	<p>Spinal compression fracture;</p> <p>Tendon rupture (particularly of the Achilles tendon);</p> <p>Pathological fracture;</p> <p>Vertebral and long bone fractures.</p>

System Organ Class	Frequency Not Known (Cannot be estimated from available data)
Investigations	<p>Intraocular pressure increased;</p> <p>Carbohydrate tolerance decreased;</p> <p>Increased insulin requirement (or oral hypoglycemic agents in diabetics);</p> <p>Blood potassium decreased which are correctable and largely preventable by restricting sodium intake to 500 mg per day and supplementing potassium intake;</p> <p>Nitrogen balance negative (due to protein catabolism);</p> <p>Negative calcium balance;</p> <p>Urine calcium increased;</p> <p>Alanine aminotransferase increased;</p> <p>Aspartate aminotransferase increased;</p> <p>Blood alkaline phosphatase increased;</p> <p>Abnormal fat deposits;</p> <p>Weight increased;</p> <p>Elevation in serum liver enzyme levels (usually reversible upon discontinuation);</p> <p>Spermatozoa progressive motility abnormal / sperm concentration abnormal.</p> <p>EEG abnormalities.</p>
Metabolism and nutrition disorders	<p>Sodium retention;</p> <p>Fluid retention;</p> <p>Alkalosis hypokalemic;</p> <p>Glucose tolerance impaired;</p> <p>Increased appetite.</p> <p>Anorexia (which may result in weight loss);</p> <p>All glucocorticoids increase gluconeogenesis. Glucose tolerance and sensitivity to insulin are decreased but provided pancreatic islet function is normal carbohydrate metabolism will not be noticeably deranged. Steroid diabetes, has been reported to develop in one fifth of patients treated with high glucocorticoid dosage;</p> <p>High dose corticosteroid therapy may induce marked</p>

System Organ Class	Frequency Not Known (Cannot be estimated from available data)
	hypertriglyceridaemia with milky plasma.
Musculoskeletal and connective tissue disorders	Myopathy; Muscular weakness; Osteonecrosis of femoral and humeral heads; Osteoporosis; Growth retardation; Neuropathic arthropathy; Muscle atrophy. Myalgia.
Neoplasms benign, malignant and unspecified (including cysts and polyps)	Kaposi's sarcoma (has been reported to occur in patients receiving glucocorticoid therapy)
Nervous system disorders	Intracranial pressure increased with papilloedema (benign intracranial hypertension) usually following discontinuation of treatment; Convulsions; Aggravation of epilepsy; Dizziness; Headache; Neuritis; Neuropathy peripheral; Paraesthesia; Vertigo; Arachnoiditis; Meningitis; Paraparesis/paraplegia; Epidural lipomatosis. Increased motor activity; Ischemic neuropathy; Restlessness.
Psychiatric disorders	Psychic derangements/psychotic manifestations (Euphoric mood, Insomnia, Mood swings, Personality change, Depression, Exacerbation of preexisting Affect

System Organ Class	Frequency Not Known (Cannot be estimated from available data)
	lability or Psychotic behaviour) Suicidal ideation; Mania; Delusions; Hallucinations; Irritability; Anxiety; Psychological dependence; Cognitive dysfunction; Nervousness; Paranoid states; Acute toxic psychoses; The absence of a history of psychiatric illness is no guarantee against the occurrence of psychosis during hormonal therapy.
Reproductive system and breast disorders	Menstruation irregular. Amenorrhea.
Renal and urinary disorders	Glycosuria.
Skin & subcutaneous tissue disorders	Petechiae; Ecchymosis; Cutaneous and subcutaneous atrophy; Skin atrophy; Acne; Dermatitis allergic; Burning sensation or tingling (especially in the perineal area, after intravenous injection); Dry skin / Skin exfoliation; Erythema; Skin hyperpigmentation; Skin hypopigmentation; Hyperhidrosis; Rash;

System Organ Class	Frequency Not Known (Cannot be estimated from available data)
	Skin striae; Alopecia; Facial erythema; Hypertrichosis. Bruising; Telangiectasia; Pruritis; Facial plethora; An acneiform eruption on the face, chest and back; Corticosteroid induced purpura resembles senile purpura. This purpura usually occurs on extensor surfaces, dorsum of the hand, and radial aspect of the forearm.
Vascular disorders	Hypertension; Circulatory collapse; Fat embolism; Embolism; Thrombophlebitis; Vasculitis. Thromboembolism.

Withdrawal symptoms: Too rapid a reduction of prednisone following prolonged treatment can lead to acute adrenal insufficiency, hypotension and death. A steroid withdrawal syndrome seemingly unrelated to adrenocortical insufficiency may also occur and include symptoms such as anorexia, nausea, vomiting, lethargy, headache, fever, weight loss, and/or hypotension. See [7 WARNINGS AND PRECAUTIONS, General, Withdrawal Symptoms](#).

8.5 Post-Market Adverse Reactions

Cardiac disorders: Bradycardia has been reported following high doses (frequency ‘unknown’).

Eye disorders: Blurred vision.

Renal and urinary disorders: Scleroderma renal crisis (frequency ‘unknown’).

Amongst the different subpopulations the occurrence of scleroderma renal crisis varies. The highest risk has been reported in patients with diffuse systemic sclerosis. The lowest risk has been reported in patients with limited systemic sclerosis (2%) and juvenile onset systemic

sclerosis (1%).

9 DRUG INTERACTIONS

9.2 Drug Interactions Overview

Prednisone is a cytochrome P450 enzyme (CYP) substrate and is mainly metabolized by the CYP3A4 enzyme. CYP3A4 is the dominant enzyme of the most abundant CYP subfamily in the liver of adult humans. It catalyzes 6 β -hydroxylation of steroids, the essential Phase I metabolic step for both endogenous and synthetic glucocorticoids. Many other compounds are also substrates of CYP3A4, some of which (as well as other drugs) have been shown to alter glucocorticoid metabolism by induction (upregulation) or inhibition of the CYP3A4 enzyme.

CYP3A4 INHIBITORS – Drugs that inhibit CYP3A4 activity generally decrease hepatic clearance and increase the plasma concentration of CYP3A4 substrate medications, such as prednisone. In the presence of a CYP3A4 inhibitor, the dose of prednisone may need to be titrated to avoid steroid toxicity.

CYP3A4 INDUCERS – Drugs that induce CYP3A4 activity generally increase hepatic clearance, resulting in decreased plasma concentration of medications that are substrates for CYP3A4. Coadministration may require an increase in prednisone dosage to achieve the desired result.

CYP3A4 SUBSTRATES – In the presence of another CYP3A4 substrate, the hepatic clearance of prednisone may be affected, with corresponding dosage adjustments required. It is possible that adverse events associated with the use of either drug alone may be more likely to occur with coadministration.

NON-CYP3A4-MEDIATED EFFECTS – Other interactions and effects that occur with prednisone are described in the Table below. See [9.4 Drug-Drug Interactions](#).

9.3 Drug-Behavioural Interactions

The risk of gastrointestinal ulceration or hemorrhage is increased when alcohol is used concurrently with glucocorticoids.

9.4 Drug-Drug Interactions

The drugs listed in this table are based on either drug interaction case reports or studies, or potential interactions due to the expected magnitude and seriousness of the interaction (i.e., those identified as contraindicated).

Table 3 - Established or Potential Drug-Drug Interactions

Proper/Common name	Source of Evidence	Effect	Clinical comment
Antacids	T	Concurrent use of antacids with APO-PREDNISONONE may decrease absorption of these glucocorticoids – efficacy may be decreased.	Dosage adjustments are required in patients receiving small doses of APO-PREDNISONONE.
Antibacterial -ISONIAZID	T	CYP3A4 INHIBITOR. See 9.2 Drug Interactions Overview, CYP3A4 INHIBITORS . In addition, there is a potential effect of glucocorticoids to increase the acetylation rate and clearance of isoniazid.	In the presence of a CYP3A4 inhibitor, the dose of APO-PREDNISONONE may need to be titrated to avoid steroid toxicity.
Antibiotic -RIFAMPIN, RIFABUTIN	T	CYP3A4 INDUCER. See 9.2 Drug Interactions Overview, CYP3A4 INDUCERS .	Coadministration may require an increase in APO-PREDNISONONE dosage to achieve the desired result.
Anticholinergics -NEUROMUSCULAR BLOCKERS	T	Glucocorticoids may influence the effect of anticholinergics. 1) An acute myopathy has been reported with the concomitant use of high doses of glucocorticoids and anticholinergics, such as neuromuscular blocking drugs. 2) Antagonism of the neuromuscular blocking effects of pancuronium and vecuronium has been reported in patients taking glucocorticoids. This interaction may be expected with all competitive neuromuscular blockers.	-

Proper/Common name	Source of Evidence	Effect	Clinical comment
Anticholinesterases	T	Steroids may reduce the effects of anticholinesterases in myasthenia gravis. Concomitant use of anticholinesterase agents and glucocorticoids may produce severe weakness in patients with myasthenia gravis.	If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating glucocorticoid therapy.
Anticoagulants (oral)	T	The effect of glucocorticoids on oral anticoagulants is variable. There are reports of enhanced as well as diminished effects of anticoagulants when given concurrently with glucocorticoids. Coadministration of glucocorticoids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports.	Coagulation indices should be monitored frequently to maintain the desired anticoagulant effect.
Anticonvulsant -CARBAMAZEPINE	T	CYP3A4 INDUCER (and SUBSTRATE). See 9.2 Drug Interactions Overview, CYP3A4 INHIBITORS, CYP3A4 SUBSTRATES .	Dosage adjustments may be required.
Anticonvulsants -PHENYTOIN, PRIMIDONE	T	CYP3A4 INDUCERS. See 9.2 Drug Interactions Overview, CYP3A4 INDUCERS .	Coadministration may require an increase in APO-PREDNISONE dosage to achieve the desired result.

Proper/Common name	Source of Evidence	Effect	Clinical comment
Antidiabetics	T	Glucocorticoids may increase blood glucose concentrations.	Dosage adjustments of antidiabetic agents may be required.
Antiemetic -APREPITANT, -FOSAPREPITANT	T	CYP3A4 INHIBITORS (and SUBSTRATES). See 9.2 Drug Interactions Overview, CYP3A4 INHIBITORS, CYP3A4 SUBSTRATES .	The dose of APO-PREDNISONONE may need to be titrated.
Antifungal drugs -ITRACONAZOLE, -KETOCONAZOLE	T	CYP3A4 INHIBITORS (and SUBSTRATE). See 9.2 Drug Interactions Overview, CYP3A4 INHIBITORS, CYP3A4 SUBSTRATES . Ketoconazole has been reported to significantly decrease the metabolism of certain glucocorticoids by up to 60%, leading to an increased risk of glucocorticoid side effects.	The dose of APO-PREDNISONONE may need to be titrated.
Antitubercular drugs	T	Serum concentrations of isoniazid may be decreased.	-
Antivirals -HIV-PROTEASE INHIBITORS	T	CYP3A4 INHIBITORS (and SUBSTRATES). See 9.2 Drug Interactions Overview, CYP3A4 INHIBITORS, CYP3A4 SUBSTRATES . 1) Protease inhibitors, such as indinavir and ritonavir, may increase plasma concentrations of glucocorticoids. 2) Glucocorticoids may induce the metabolism of HIV-protease inhibitors resulting in reduced plasma concentrations.	The dose of APO-PREDNISONONE may need to be titrated.

Proper/Common name	Source of Evidence	Effect	Clinical comment
Aromatase inhibitor -AMINOGLUTETHIMIDE	T	Aminoglutethimide-induced adrenal suppression may exacerbate endocrine changes caused by prolonged glucocorticoid treatment. Aminoglutethimide may lead to a loss of glucocorticoid-induced adrenal suppression. Aminoglutethimide may reduce the therapeutic efficacy of corticosteroids by increasing the rate of metabolism.	
Barbiturates -PHENOBARBITAL	T	CYP3A4 INDUCERS. See 9.2 Drug Interactions Overview, CYP3A4 INDUCERS .	Coadministration may require an increase in APO-PREDNISONE dosage to achieve the desired result.
Calcium Channel Blocker -DILTIAZEM	T	CYP3A4 INHIBITOR (and SUBSTRATE). See 9.2 Drug Interactions Overview, CYP3A4 INHIBITORS, CYP3A4 SUBSTRATES .	The dose of APO-PREDNISONE may need to be titrated.
CHOLESTYRAMINE	T	Cholestyramine may increase the clearance of glucocorticoids.	-

Proper/Common name	Source of Evidence	Effect	Clinical comment
Contraceptives (oral) -ETHINYLESTRADIOL/ NORETHINDRONE	T	<p>CYP3A4 INHIBITOR (and SUBSTRATE). See 9.2 Drug Interactions Overview, CYP3A4 INHIBITORS, CYP3A4 SUBSTRATES.</p> <p>Estrogens may decrease the hepatic metabolism of certain glucocorticoids, thereby increasing their effect.</p>	The dose of APO-PREDNISONONE may need to be titrated.
Cytotoxic agents -METHOTREXATE	T	There is an increased risk of hematological toxicity when APO-PREDNISONONE is given with methotrexate.	-
Digitalis glycosides	T	Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia.	In patients taking these drug therapy combinations serum electrolytes, particularly potassium levels, should be monitored closely.

Proper/Common name	Source of Evidence	Effect	Clinical comment
Immunosuppressant -CYCLOSPORINE	T	<p>CYP3A4 INHIBITOR (and SUBSTRATE). See 9.2 Drug Interactions Overview, CYP3A4 INHIBITORS, CYP3A4 SUBSTRATES.</p> <p>1) Mutual inhibition of metabolism occurs with concurrent use of cyclosporine and prednisone, which may increase the plasma concentrations of either or both drugs. Therefore, it is possible that adverse events associated with the use of either drug alone may be more likely to occur upon coadministration.</p> <p>2) Convulsions have been reported with concurrent use of methylprednisolone and cyclosporine.</p> <p>3) Increased activity of both cyclosporine and prednisone may occur when the two are used concurrently. Convulsions have been reported with concurrent use.</p>	The dose of APO-PREDNISONE may need to be titrated.
Immunosuppressant -CYCLOPHOSPHAMIDE TACROLIMUS	T	CYP3A4 SUBSTRATE. See 9.2 Drug Interactions Overview, CYP3A4 SUBSTRATES .	In the presence of another CYP3A4 substrate, the hepatic clearance of APO-PREDNISONE may be affected, with corresponding dosage adjustments required.

Proper/Common name	Source of Evidence	Effect	Clinical comment
Macrolide Antibiotics -CLARITHROMYCIN -ERYTHROMYCIN	T	CYP3A4 INHIBITOR (and SUBSTRATE). See 9.2 Drug Interactions Overview, CYP3A4 INHIBITORS, CYP3A4 SUBSTRATES . Macrolide antibiotics have been reported to cause a significant decrease in glucocorticoid clearance.	The dose of APO-PREDNISONONE may need to be titrated.
Macrolide Antibiotics -TROLEANDOMYCIN	T	CYP3A4 INHIBITOR. See 9.2 Drug Interactions Overview, CYP3A4 INHIBITORS . Macrolide antibiotics have been reported to cause a significant decrease in glucocorticoid clearance.	In the presence of a CYP3A4 inhibitor, the dose of APO-PREDNISONONE may need to be titrated to avoid steroid toxicity.
Mifepristone	T	The effect of corticosteroids may be reduced for 3-4 days after mifepristone.	-
NSAIDs (nonsteroidal anti-inflammatory drugs) -high-dose ASPIRIN (acetylsalicylic acid)	T	Concomitant use of aspirin (or other nonsteroidal anti-inflammatory agents) and glucocorticoids increases the risk of gastrointestinal side effects. The clearance of salicylates may be increased with concurrent use of glucocorticoids and steroid withdrawal may result in salicylate intoxication.	Aspirin should be used cautiously in conjunction with concurrent use of glucocorticoids in hypoprothrombinemia. Patients should be observed closely for adverse effects of either medicine.

Proper/Common name	Source of Evidence	Effect	Clinical comment
Potassium-depleting agents -diuretics -AMPHOTERICIN-B -xanthenes -beta2 agonists	T	When glucocorticoids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure.	-
Somatropin	T	Glucocorticoid therapy may inhibit the response.	-
Sympathomimetics -SALBUTAMOL, SALMETEROL, TERBUTALINE OR FORMOTEROL	T	There is an increased risk of hypokalemia if high doses of corticosteroids are given with high doses of salbutamol, salmeterol, terbutaline or formoterol.	-
Vaccines	T	Patients on prolonged glucocorticoid therapy may exhibit a diminished response to toxoids and live or attenuated vaccines due to inhibition of antibody response. Glucocorticoids may also potentiate the replication of some organisms contained in live attenuated vaccines.	Live vaccines should not be given to individuals with impaired immune responsiveness. Routine administration of vaccines or toxoids should be deferred until glucocorticoid therapy is discontinued if possible.

T = Theoretical

9.5 Drug-Food Interactions

Grapefruit juice is a CYP3A4 inhibitor. See [9.2 Drug Interactions Overview, CYP3A4 INHIBITORS](#).

9.6 Drug-Herb Interactions

Interactions with herbal products have not been established.

9.7 Drug-Laboratory Test Interactions

Glucocorticoids may decrease I_{131} uptake and protein-bound iodine concentrations, making it difficult to monitor the therapeutic response of patients receiving the drugs for thyroiditis.

Glucocorticoids may produce false-negative results in the nitroblue tetrazolium test for systemic bacterial infection.

Glucocorticoids may suppress reactions to skin tests.

10 CLINICAL PHARMACOLOGY

10.1 Mechanism of Action

Prednisone is a synthetic corticosteroid with predominantly glucocorticoid and some mineralocorticoid properties. Their exact mode of action is not clearly understood.

Natural and synthetic glucocorticoids have been found to bind to specific intracellular receptors upon entering target tissues. The macromolecular complex thus formed is transported into the nucleus where it interacts with chromosomal constituents to alter gene expression. These hormones alter the regulation of many cellular processes, including enzyme synthesis and activity, membrane permeability, transport processes, and structure.

Glucocorticoids are most commonly associated with the following physiological processes:

- Inhibition of inflammatory processes (such as accumulation of inflammatory cells, phagocytosis, release of inflammatory mediators, capillary dilatation, migration of leukocytes).
- Decrease the body's immune responses to diverse stimuli by decreasing production of immune response mediators (such as lymphocytes, eosinophils) and decrease immunoglobulin binding to cell surfaces.
- Inhibition of the later stages of wound healing (capillary proliferation, deposition of collagen, cicatrization).
- Anti-insulin activity, promotion of gluconeogenesis, inhibition of glucose utilization, stimulation of fat synthesis and storage.
- Stimulation of the secretion of various components of gastric juice.
- Increased glomerular filtration rate and resulting increase in urinary excretion of urate (creatinine excretion remains unchanged).
- Calcium loss.
- Suppression of ACTH production.
- Stimulation of erythropoiesis.

Prednisone's mineralocorticoid activity can also affect the following physiological processes:

- Stimulation of sodium retention.
- Stimulation of intracellular potassium loss.

See [10.2 Pharmacodynamics](#).

10.2 Pharmacodynamics

Corticosteroids are hormonal steroids released by the adrenal gland, which are classified into glucocorticoids and mineralocorticoids. The main naturally occurring glucocorticoids include cortisol and cortisone.

Glucocorticoids have widespread effects because they influence the function of most cells in the body. While some effects are dose-dependent, others are not further stimulated in the presence of high pharmacological amounts. Glucocorticoids also possess some mineralocorticoid activity.

Prednisone is a synthetic glucocorticoid with about 5 times greater glucocorticoid activity than cortisone, but without a correspondingly increasing the mineralocorticoid activity.

Anti-inflammatory Effects

Glucocorticoids decrease or prevent tissue responses to inflammatory processes, thereby reducing development of symptoms of inflammation without affecting the underlying cause. They inhibit accumulation of inflammatory cells, including macrophages and leukocytes, at sites of inflammation. They also inhibit phagocytosis, lysosomal enzyme release, and synthesis and/or release of several chemical mediators of inflammation. Although the exact mechanisms are not completely understood, actions that may contribute significantly to these effects include blockade of the action of macrophage inhibitory factor, leading to inhibition of macrophage localization; reduction of dilatation and permeability of inflamed capillaries and reduction of leukocyte adherence to the capillary endothelium, leading to inhibition of both leukocyte migration and edema formation; and increased synthesis of lipomodulin (macrocortin), an inhibitor of phospholipase A₂-mediated arachidonic acid release from membrane phospholipids, with subsequent inhibition of the synthesis of arachidonic acid-derived mediators of inflammation (prostaglandins, thromboxanes, and leukotrienes).

Immunosuppressant actions may also contribute significantly to the anti-inflammatory effect.

Immunosuppressant Effects

Mechanisms of immunosuppressant action are not completely understood but may involve prevention or suppression of cell-mediated (delayed hypersensitivity) immune reactions as well as more specific actions affecting the immune response. Glucocorticoids reduce the concentration of thymus-dependent lymphocytes (T-lymphocytes), monocytes, and eosinophils. They also decrease binding of immunoglobulin to cell surface receptors and inhibit the synthesis and/or release of interleukins, thereby decreasing T-lymphocyte blastogenesis and reducing expansion of the primary immune complexes through basement membranes and decrease concentrations of complement components and immunoglobulins.

Glucocorticoids generally do not interfere with the development of acquired immunity. Experimentally, however, large doses given with the stimulus can inhibit the normal antibody response. Delayed hypersensitivity can be inhibited.

Glucocorticoids markedly inhibit homograft rejection reactions and are employed for this purpose in the treatment of patients receiving organ transplants. They may work by reducing the amount of antigen liberated by the grafted tissue; by delaying revascularization; and by interfering with the sensitization of antibody-forming cells.

Gluconeogenesis Effects

Glucocorticoids have important effects on intermediary metabolism. They contribute to insulin resistance and stimulate the production of glucose (gluconeogenesis) from proteins. The increase of circulating glucose stimulates the production of insulin, further contributing to hyperinsulinemia, and leads to the deposition of fat, particularly in the trunk, face, and mesentery.

Effects on Electrolyte Balance

Glucocorticoids are associated with some mineralocorticoid activity, which can cause a disturbance of electrolyte balance. This is manifest in the retention of sodium and water, with edema and hypertension, and in the increased excretion of potassium with the possibility of hypokalemic alkalosis. In extreme cases, ECG changes and cardiac failure may be induced.

Other Effects

Glucocorticoids cause inhibition of the later stages of wound healing (capillary proliferation, deposition of collagen, cicatrization).

Glucocorticoids have an inhibitory effect on the secretion of ACTH by the anterior pituitary gland.

Large doses of glucocorticoids stimulate excessive production of acid and pepsin in the stomach and stimulate the formation of peptic ulcer.

Glucocorticoids facilitate fat absorption.

Glucocorticoids appear to antagonize the effect of vitamin D on calcium absorption and increase calcium loss.

Glucocorticoids can stimulate erythropoiesis and increase the production of neutrophils and platelets.

10.3 Pharmacokinetics

Absorption

Synthetic glucocorticoids are rapidly and completely absorbed when given by orally. Prednisone has a pre-conversion biological half-life of about 60 minutes.

Distribution

They are rapidly distributed to muscles, liver, skin, intestine and kidneys. They bind to plasma proteins to varying extents. Because only unbound drug is pharmacologically active, patients with low serum albumin concentrations may be more susceptible to the effects of glucocorticoids than patients with normal serum albumin concentrations. The plasma half-life after oral administration ranges from 3 to 4 hours. Oral bioavailability varies widely between

subjects.

Metabolism

Prednisone is converted via hepatic metabolism to its pharmacologically active form, prednisolone. Prednisolone is then metabolized, also in the liver, to biologically inactive compounds, primarily glucuronides and sulfates.

Elimination

Prednisone inactive metabolites and small amounts of unmetabolized drug are excreted in urine by the kidneys. Small amounts of unmetabolized drug are also excreted in bile.

Special populations and Conditions

- **Pediatrics (6 to 18 years of age):** In order to minimize the potential growth effects of glucocorticoids, pediatric patients should be titrated to the lowest effective dose over the shortest period of time. See [4.2 Recommended Dose and Dosage Adjustment, Pediatric dose](#) and [7.1.3 Pediatrics](#).
- **Geriatrics (> 65 years of age):** Dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. See [4.2 Recommended Dose and Dosage Adjustment, Geriatric dose](#) and [7.1.4. Geriatrics](#).
- **Sex:** This information is not available for this drug product.
- **Pregnancy and Breast-feeding:** Prednisone should be used in pregnancy or by women of child bearing potential only if clearly needed and the potential benefit justifies the potential risk to the mother and embryo or fetus. See [7.1.1 Pregnant Women](#).

Glucocorticoids cross the placenta and may be distributed into breast milk. Glucocorticoids should be administered to breast-feeding mothers only if the benefits of therapy to the mother are judged to outweigh the potential risks to the infant. See [7.1.2 Breast-feeding](#).
- **Genetic Polymorphism:** This information is not available for this drug product.
- **Ethnic Origin:** This information is not available for this drug product.
- **Hepatic Insufficiency:** Use with caution in patients with impaired hepatic function, a reduction of dosage may be necessary. See [7 WARNINGS AND PRECAUTIONS, Hepatic/Biliary/Pancreatic](#).
- **Renal Insufficiency:** Prednisone should be used with caution in patients with renal insufficiency. See [7 WARNINGS AND PRECAUTIONS, Renal](#).
- **Obesity:** This information is not available for this drug product.

11 STORAGE, STABILITY AND DISPOSAL

Store at room temperature 15°C to 30°C.

Keep out of reach and sight of children.

12 SPECIAL HANDLING INSTRUCTIONS


None.

PART II: SCIENTIFIC INFORMATION

13 PHARMACEUTICAL INFORMATION

Drug Substance

Proper name:	Prednisone
Chemical name:	(1) Pregna-1,4-diene-3,11,20-trione; (2) 17,21-Dihydroxypregna-1,4-diene-3,11,20-trione.
Molecular formula and molecular mass:	$C_{21}H_{26}O_5$ and 358.44 g/mol
Structural formula:	



Physicochemical properties: White to practically white, crystalline powder.

14 CLINICAL TRIALS

The clinical trial data on which the original indication was authorized is not available.

15 MICROBIOLOGY

No microbiological information is required for this drug product.

16 NON-CLINICAL TOXICOLOGY

General Toxicology

Based on conventional studies of safety pharmacology, repeated-dose toxicity, no unexpected hazards were identified. The toxicities seen in the repeated-dose studies are those expected to occur with continued exposure to exogenous adrenocortical steroids.

Carcinogenicity

Long-term studies in animals have not been performed to evaluate carcinogenic potential.

Genotoxicity

There was no evidence of a potential for genetic and chromosome mutations when tested in limited studies performed in bacterial and mammalian cells.

Reproductive and Developmental Toxicology

Glucocorticoids have been shown to reduce fertility when administered to both male and female rats.

Glucocorticoids have been shown to be teratogenic in many species when given in doses equivalent to the human dose. In animal studies, glucocorticoids readily cross the placenta and have been shown to be teratogenic in many species when given in doses equivalent to human dose. Glucocorticoids given to pregnant mice, rats, and rabbits have yielded an increase incidence of malformations in the offspring (cleft palate, skeletal malformations) and intra-uterine growth retardation.

Special Toxicology

Information is not available.

Juvenile Toxicity

Information is not available.

PATIENT MEDICATION INFORMATION

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

Pr **APO-PREDNISONONE**

Prednisone Tablets

Read this carefully before you start taking **APO-PREDNISONONE** and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about **APO-PREDNISONONE**.

Serious Warnings and Precautions

APO-PREDNISONONE can cause serious side effects, including:

- **Pheochromocytoma crisis:** Pheochromocytoma crisis (rare tumor of the adrenal gland), a fatal condition, has been reported in patients taking APO-PREDNISONONE. Talk to your healthcare professional if you have a tumor of the adrenal glands.
- **Viral infections:** Taking APO-PREDNISONONE with other medicines that weaken your immune system may increase your risk of infections. Viral infections, including chickenpox and measles, can have a more severe or even fatal course if you are not immune and are taking other medicines that weaken your immune system.
- **Scleroderma Kidney Crisis:** Your risk of developing scleroderma kidney crisis is higher if you have systemic sclerosis (chronic immune system disease) and are taking a daily dose of 15 mg or more of APO-PREDNISONONE. This may be life threatening. This disease hardens and tightens skin, increases your blood pressure and causes you to make less urine.
- **Strongyloides (threadworm) infestation:** Talk to your healthcare professional if you have or had a threadworm (Strongyloides) infection. Taking APO-PREDNISONONE if you have a threadworm infection, can lead to the rapid growth and spread of the parasite. This can result in serious side effects, such as, inflammation of the intestines (enterocolitis) and a potentially life-threatening bloodstream infection.

What is APO-PREDNISONONE used for?

APO-PREDNISONONE is used in adults and children 6 years of age and older to treat many different conditions. These include allergy and inflammation.

How does APO-PREDNISONONE work?

APO-PREDNISONONE is a corticosteroid. It decreases the body's reaction to some diseases and reduces inflammation. It is only able to prevent or reduce symptoms of your condition, it does not cure it.

What are the ingredients in APO-PREDNISONONE?

Medicinal ingredients: prednisone

Non-medicinal ingredients: croscarmellose sodium, lactose, magnesium stearate, microcrystalline cellulose.

APO-PREDNISONONE comes in the following dosage forms:

Tablets: 1 mg, 5 mg and 50 mg

Do not use APO-PREDNISONONE if you:

- are allergic to prednisone, any other corticosteroid medicine or any of the ingredients in the APO-PREDNISONONE tablet.
- have a systemic fungal infection (a fungal infection that has spread throughout your body).
- have a viral infection, such as measles, chickenpox or herpes simplex of the eye.
- have recently received, or will receive, a type of vaccine called a live, or live/attenuated vaccine.
- have stomach or gut problems, such as an ulcer, ulcerative colitis or diverticulitis.
- have a bacterial or viral infection that is not being treated.
- have pancreatitis. Except pancreatitis caused by sarcoidosis (an inflammatory disease).

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take APO-PREDNISONONE. Talk about any health conditions or problems you may have, including if you:

- have an infection, such as tuberculosis.
- have a bleeding or blood clotting problem.
- have osteoporosis (thin, fragile bones).
- have high blood pressure.
- have seizures (convulsions) or other neurological problems.
- have a thyroid problem (hypothyroidism).
- have a condition called myasthenia gravis that causes muscle pain, stiffness or weakness.
- have skin cancer (Kaposi's sarcoma).
- have heart problems such as heart failure or have had a heart attack.
- have eye problems, such as ocular herpes simplex, glaucoma, cataracts, or any problems with the retina.
- have kidney disease.
- have received vaccines for smallpox, measles or chickenpox in the past.
- have liver problems such as cirrhosis.
- have mental health problems, such as feeling high (euphoria), depression, trouble sleeping, mood swings.

- have low levels of potassium or calcium in your blood.
- have stomach or gut problems.
- have Cushing’s disease, a condition where your body produces too much cortisol.
- have a weak immune response.
- have high blood sugar or are experiencing high levels of stress or have recently had surgery, an infection or experienced trauma.
- have a family history of diabetes.
- have muscle weakness and wasting caused by Duchenne’s muscular dystrophy or long term use of corticosteroids.
- have skin problems.
- are 65 years of age or older.

Other warnings you should know about:

You should tell any other healthcare professional that you see that you are being, or have been treated, with APO-PREDNISONONE.

Driving and Using Machines: APO-PREDNISONONE is likely to affect your ability to drive or use machines. Do not drive, operate machinery, or participate in any dangerous activities where alertness is required, until you know how APO-PREDNISONONE affects you.

Surgery: Before you have any type of surgery, including dental procedures, tell your healthcare professional or dentist that you are taking APO-PREDNISONONE.

Stopping treatment: Stopping treatment with APO-PREDNISONONE should be gradual. Your healthcare professional will determine how to stop your treatment. If you suddenly stop taking APO-PREDNISONONE, you may experience:

- **Adrenal insufficiency**, a condition where your body does not make enough of the cortisol hormone. This includes symptoms such as fainting, weakness, restlessness, nausea, vomiting, headache, dizziness, muscle weakness or joint pain.
- **Withdrawal syndrome.** This includes symptoms such as nausea, fatigue, decreased appetite, anorexia, shortness of breath, low blood pressure, low blood sugar levels, muscle pain, mood changes, fever, dehydration, general discomfort, joint pain, dizziness, peeling of skin and fainting.
- Tell your healthcare professional right away if you experience any of these symptoms after changing or stopping your treatment. Some of these symptoms can last for months after you stop taking APO-PREDNISONONE.

Infections: Treatment with APO-PREDNISONONE may reduce your body’s ability to fight infections. This can sometimes lead to infections caused by germs that rarely cause infection under normal situations.

- Taking APO-PREDNISONONE with other medicines that weaken your immune system may increase your risk of infections.
- During treatment, avoid contact with anyone who has chickenpox, shingles or measles. If you were in contact with any of these infections, talk to your healthcare professional right away, even if there are no symptoms.

- The signs and symptoms of infections such as fever or inflammation may be hidden by the anti-inflammatory action of APO-PREDNISONONE. You should talk to your healthcare professional if you have any symptoms of an infection.
- Do not have any immunizations (particularly with "live" vaccines such as measles, oral polio or yellow fever) without talking to your healthcare professional while you are being treated with APO-PREDNISONONE.

Pregnancy and breastfeeding:

- If you are pregnant or planning on becoming pregnant while taking APO-PREDNISONONE, there are specific risks that you should discuss with your healthcare professional.
- This medicine can cross the placenta and harm your baby.
- Tell your healthcare professional right away if you become pregnant while taking APO-PREDNISONONE.
- APO-PREDNISONONE can pass into your breast milk and harm your baby. Before taking this medicine, talk to your healthcare professional about the best way to feed your baby during treatment.

Fertility: APO-PREDNISONONE may reduce fertility in both male and female patients. It can cause irregular periods in women and abnormal sperm in men.

Children: Corticosteroids can affect growth in children. Your healthcare professional will regularly monitor growth and development in growing children.

Lab tests and monitoring:

- If you are going to have a skin test for allergies or test for bacterial infection, tell your healthcare professional as APO-PREDNISONONE may interfere with the results.
- You should monitor your fluid retention by recording your weight daily, observing your fluid intake and output.
- Your blood pressure and kidney will be routinely checked by your healthcare professional.

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

The following may interact with APO-PREDNISONONE:

- alcohol
- grapefruit or grapefruit juice.
- medicines used to treat glaucoma, such as acetazolamide.
- medicines used to "thin" the blood and prevent blood clots, such as warfarin, coumadin.
- medicines used to treat myasthenia gravis, such as distigmine, neostigmine.
- antibiotics used to treat bacterial infections, such as isoniazid, erythromycin, clarithromycin, troleandomycin, rifampicin, rifabutin.
- acetylsalicylic acid and non-steroidal anti-inflammatory drugs (NSAIDs), used to treat

fever and inflammation, such as ibuprofen.

- antacids used to treat stomach upset and heart burn such as calcium carbonate, magnesium hydroxide, or aluminum hydroxide.
- medicines used during surgery, such as pancuronium, vecuronium.
- medicines that treat skeletal muscle weakness, such as anticholinesterases.
- medicines used to prevent or alleviate nausea and vomiting, such as aprepitant.
- medicines used to treat inflammatory conditions, such as methylprednisolone.
- medicines used to treat epilepsy, such as barbiturates, carbamazepine, primidone, phenytoin, phenobarbital.
- medicines used to treat fungal infections, such as ketoconazole, itraconazole, amphotericin-B.
- medicines used to treat auto-immune disorders, such as cyclosporine, tacrolimus, cyclophosphamide.
- Mifepristone, the medicine used in aborting a pregnancy
- medicines used to treat breathing problems like asthma and COPD.
- medicines used to treat heart problems or high blood pressure, such as digoxin, diltiazem, salbutamol, salmeterol, terbutaline, formoterol.
- medicines used to treat high cholesterol, such as cholestyramine.
- medicines used to treat high blood pressure called “water pills” or diuretics.
- medicines used to treat HIV infections, such as indinavir, ritonavir.
- hormones, such as estrogen, oral birth control pills, growth hormone (somatropin).
- medicines used to treat diabetes.
- medicines used to treat tuberculosis.
- medicines used to treat various types of cancer, such as methotrexate, aminoglutethimide.
- vaccines.

How to take APO-PREDNISONE:

- Take APO-PREDNISONE exactly as directed by your healthcare professional.
- How often you take APO-PREDNISONE may vary depending on the condition being treated. It can be taken once daily, several times a day or on alternate days (every other day). Your healthcare professional will decide on the schedule that is best for you.
- Your healthcare professional may need to change your dose temporarily during treatment depending on your response, other conditions that you have and any side-effects you might experience.
- APO-PREDNISONE should **not** be stopped abruptly. Do not stop taking APO-PREDNISONE without talking to your healthcare professional.
- APO-PREDNISONE tablets should be taken orally, with water.

Usual dose:

Adults and Children 6 years of age and older: Your healthcare professional will decide on the dose that is right for you based on the condition being treated and your response to the

treatment. They will prescribe the smallest possible dose.

Your healthcare professional might adjust your initial dose until you have a satisfactory response. When your condition has improved, your healthcare professional will reduce your dose gradually.

Overdose:

If you think you, or a person you are caring for, have taken too much APO-PREDNISONONE, contact a healthcare professional, hospital emergency department, regional poison control centre or Health Canada's toll-free number, 1-844 POISON-X (1-844-764-7669) immediately, even if there are no signs or symptoms.

Missed Dose:

If you miss a dose, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and continue your regular dosing schedule. Do not take a double dose to make up for a missed one.

What are possible side effects from using APO-PREDNISONONE?

These are not all the possible side effects you may have when taking APO-PREDNISONONE. If you experience any side effects not listed here, talk to your healthcare professional.

Side effects may include:

- abdominal pain, nausea, vomiting, diarrhea
- blurred vision
- constipation, bloating, indigestion, change in taste
- increased appetite, weight gain
- hiccups
- change in strength and reflexes, loss of muscle mass
- muscle pain and weakness
- confusion, forgetfulness
- dizziness, vertigo
- headache
- feeling of general discomfort or uneasiness
- increased sweating
- Increased physical movement
- loss of appetite
- restlessness
- wasting or shrinkage of tissues, organs, or muscles
- thinning hair, unusual hair growth, excessive hair growth in women
- slow wound healing, thin, fragile skin
- feeling tired

APO-PREDNISONE can cause abnormal lab tests including high fats in your blood and sugar in your urine. Your healthcare professional will decide when to perform lab tests and interpret the results.

Serious side effects and what to do about them:

Symptom / Effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
UNKNOWN FREQUENCY			
Adrenal insufficiency (low levels of cortisol produced by the adrenal glands): fainting, weakness, restlessness, nausea, vomiting, headache, dizziness, muscle weakness, joint pain			√
Hypothyroidism (low level of parathyroid hormone): low calcium level, muscle spasm, twitching, brittle nails, tingling sensation in hands, feet, mouth, memory problems, depression.		√	
Slowed growth in children		√	
Scleroderma kidney crisis in patients already suffering from scleroderma (an autoimmune disease): sudden increase in blood pressure, kidney failure, hardened and tightened skin.			√
Allergic reaction and Angioedema (swelling of the tissue under the skin): swelling of the hands, feet, ankles, genitals, face, lips, tongue, or throat, difficulty swallowing or breathing, itching, hives, rash, swelling of the digestive tract			√

Symptom / Effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
causing diarrhea, nausea, vomiting			
Bradycardia (slow heart rate): fainting, dizziness, shortness of breath, fatigue, or chest pain		√	
Congestive heart failure (heart does not pump blood as well as it should): shortness of breath, fatigue and weakness, cough, rapid or irregular heartbeat			√
Cushing's syndrome (high blood cortisol): round "moon" face, rapid weight gain especially around the body, excess sweating, thinning of the skin, easy bruising, dry skin, stretch marks, muscle weakness, fat deposits between the shoulder blades (buffalo hump), wounds that are slow to heal		√	
Deep vein thrombosis (blood clot in the arm or leg): pain, tenderness, or swelling in your arm or leg, difficulty standing or walking, feeling of warmth in the arm or leg, red or discolored skin			√
Edema: fluid retention, swelling of the hands, legs, or feet, muscle pain or cramps		√	
Eye problems: <ul style="list-style-type: none"> • Glaucoma: increased pressure in your eyes, eye and head pain, swelling or redness in or around the eye, changes in vision, hazy 		√	

Symptom / Effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
<p>or blurred vision, sudden vision loss</p> <ul style="list-style-type: none"> • Cataracts: clouding of the lens, blurry vision, dim vision, eye pain • Central serous chorioretinopathy (CSCR): blurry vision or other changes in vision • Infections: redness, swelling, discharge, eye pain, infections of the eye caused by viruses or fungi • Corneal or scleral thinning: clear front part and the whites of the eye become thinner 			
<p>Gastrointestinal perforation (a hole in the wall of your stomach or bowels): severe abdominal pain and tenderness, nausea, vomiting, chills or fever, diarrhoea, gastric irritation, constipation, esophageal thrush (fungal infection of the esophagus caused by Candida), larger liver</p>			√
<p>Heart attack: pressure or squeezing pain between the shoulder blades, in the chest, jaw, left arm or upper abdomen, shortness of breath, dizziness, fatigue, light-headedness, clammy skin, sweating, indigestion, anxiety, feeling faint, irregular heartbeat</p>			√

Symptom / Effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
Infections: fever, chills, feeling unwell, sore throat, body aches, fatigue			√
Intracranial hypertension (increased pressure inside the skull and around the brain that can cause brain injury): severe headache, burning or prickling sensation in hands, arms and legs, weakness or paralysis of the legs, vision changes, sudden loss of vision, nausea, vomiting, dizziness			√
Latent (delayed) Diabetes / High blood sugar: increased thirst, frequent urination, dry skin, headache, blurred vision, fatigue, tingling or numbness in the hands or feet	√		
Mental health problems: feeling depressed including thinking about suicide, feeling anxious, difficulty sleeping (insomnia), having delusions and/or hallucinations, mood swings, personality changes, memory problems, confusion, irritability, nervousness, euphoria (intense feelings of well-being, elation, happiness, excitement, and joy), drug dependence, paranoid state, altered perception and thinking		√	
Seizures or worsened episodes of seizures: convulsions or fits with or without loss of consciousness			√
Bone problems:		√	

Symptom / Effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
<ul style="list-style-type: none"> • Osteoporosis (thin, fragile bones): broken bones, bone/joint pain, back pain that gets worse when standing or walking • Vertebra fracture: numbness or tingling in the limbs, loss of bowel or bladder control. • Long bone fracture: Swelling and inability to use the affected limb, tender to touch, deformity/ misalignment 			
Pancreatitis (inflammation of the pancreas): upper abdominal pain, fever, rapid heartbeat, nausea, vomiting, tenderness when touching the abdomen			√
Pulmonary embolism (blood clot in the lung): sharp pain in the chest, coughing blood or sudden shortness of breath			√
Reactivation of Tuberculosis: coughing blood, pain in the chest, loss of appetite, unexplained weight loss, fever, chills, night sweats			√
Irregular menstrual periods or missing of periods	√		
Skin problems: bruises or contusions, itching, spider veins, facial redness, swelling, puffiness, red or purple discolored spots , acne	√		
Stomach ulcer: severe, long-lasting stomach pain, black			√

Symptom / Effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
tarry stools or blood in stools, vomiting blood, heartburn, loss of appetite, weight loss			
Stroke (blood clot in the brain): sudden severe headache or worsening of headache, vomiting, dizziness, fainting, disturbance of vision or speech, weakness or numbness in the face, arm or leg			√
Thromboembolism (blood clot forms in a blood vessel and travels to another part of the body to block blood flow): shortness of breath, chest pain, rapid heartbeat, and swelling or pain in a limb		√	
High blood pressure: headache, shortness of breath, feeling unwell, swelling in your ankles and legs, heart palpitations		√	
Withdrawal symptoms: nausea, fatigue, decreased appetite, anorexia, shortness of breath, low blood pressure, low blood sugar levels, muscle pain, fever, general discomfort, joint pain, dizziness, peeling of skin, fainting		√	

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, talk to your healthcare professional.

Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (canada.ca/drug-device-reporting) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

NOTE: Contact your healthcare professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

Storage:

Store at room temperature 15°C to 30°C.

Keep out of reach and sight of children.

If you want more information about APO-PREDNISONE:

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes the Patient Medication Information by visiting the Health Canada Drug Product Database website: (<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>); the manufacturer's website (<http://www.apotex.ca/products>), or by calling 1-800-667-4708.

This leaflet was prepared by Apotex Inc., Toronto, Ontario, M9L 1T9.

Last Revised: OCT 02, 2025